FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research.

XST-14 is a potent, competitive, and highly selective inhibitor of ULK1 and exhibits an IC50 of 26.6 nM in an in vitro ULK1 kinase activity assay, respectively. XST-14 reduces the phosphorylation of the ULK1 downstream substrate and induces autophagy inhibition. It exhibits antitumor effects.

Pyrimidine is an endogenous metabolite. It is used to study the photoinduced ion chemistry of the halogenated pyrimidines, a class of prototype radiosensitizing molecules, and is also used to assess pyrimidine/purine asymmetry quantitatively.

LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents.

ALKBH5 inhibitor (Cpd 20m) is a potent and selective inhibitor of RNA m6A demethylase AlkB homolog 5 ALKBH5 with IC50 of 21 nM.

Sodium Montmorillonite is a layered clay mineral (2:1 phyllosilicate) that belongs to a class of the smectite group. It can be used for preparation of new drug delivery systems, especially for slow release of protonable drugs due to its high degree of surface area and high capacity for cation exchange.

Sodium alginate is a sodium salt of alginic acid, can be extracted and purified from the cell walls brown seaweed Laminaria japonica. It has chelating activity and can be used to adsorb heavy metal ions, also has mucosal-protective and hemostatic effects and used in food additives and pharmaceuticals.

NADP sodium salt, a nicotinamide adenine dinucleotide, is a coenzyme that plays a vital role in various metabolic reactions within living cells. NADP sodium salt is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP+) and reduced (NADPH).

L-Cystine dihydrochloride is used as a cell culture media component for the commercial biomanufacture of therapeutic recombinant proteins and monoclonal antibodies and as a sulfur-containing precursor of glutathione (GSH) synthesis. L-Cystine dihydrochloride homeostasis is also important for GSH functions.

L-Cysteine hydrochloride hydrate is an essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione, and taurine. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans.

MSU-42011 is an orally active agonist of retinoid X receptor (RXR). MSU-42011 inhibits the expression of iNOS and p-ERK protein. It exhibits immunomodulatory and antitumor activity. MSU-42011 can be used for cancer research.

LY3537982 (KRAS G12C inhibitor 19) is a highly selective and potent inhibitor of the  KRAS-G12C protein. LY3537982 selectively inhibits the growth of KRAS G12C mutant cells H23 G12C, H358 G12C, and H2122 G12C with IC50s of 1.04 nM, 1.16 nM, and 11.38 nM, respectively.

T1-44 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It exhibits anti-tumor activity in pancreatic cancers.

TED-642 (TED642) is a potent, covalent, pan-TEAD-YAP1 antagonist, inhibits TEAD1/2/4 binding to YAP with IC50 of 0.9-1.2 uM.

TAT-PDHPS1 is an endogenous stable peptide that inhibits the proliferation of ovarian cancer cells in vitro, regulates ovarian cancer development through targeting YAP1 signaling, binds to and interacts with protein phosphatase 2 phosphatase activator (PT

PDHPS1 is an endogenous stable peptide which is derived from the C-terminal (2090-2110) of NUMA1, inhibits the proliferation of ovarian cancer cells in vitro, regulates ovarian cancer development through targeting YAP1 signaling, binds to and interacts wi

NSC682769 is a specific YAP-TEAD signaling inhibitor, blocks the association of the YAP and TEAD interaction interface, directly binds to YAP with Kd of 738 nM.

MYF-03-69 is a selective, covalent, irreversible TEAD inhibitor, binds with TEAD palmitate pocket, disrupts YAP-TEAD association, suppresses TEAD transcriptional activity (IC50=45 nM) and inhibits cell growth of defective Hippo signaling.

mCMY020 is a potent, specific and covalent inhibitor of TEAD transcriptional activity with IC50 of 91.9-468.6 nM for TEAD1-4.

LM98 (TEAD inhibitor LM98) is a flufenamic acid analogue, shows strong affinity to TEAD, inhibits its autopalmitoylation and reduces the YAP-TEAD transcriptional activity.

AF-2112 is a small molecule inhibitor of TEAD, reduces the expression of CTGF, Cyr61, Axl and NF2, inhibits migration of human MDA-MB-231 breast cancer cells.

Ro 25-1553 is a potent, selective VIPR2 agonist and a cyclic peptide analog of vasoactive intestinal peptide (VIP), displaces the radioligand 125I-VIP from rat forebrain membranes with IC50 of 4.98 nM.

PA-915 (PA915) is a small-molecule, non-peptide antagonist of the PACAP type I (PAC1) receptor, inhibits PACAP (1 nM)-induced phosphorylation of CREB in PAC1/CHO cells with IC50 of <10 pM.

BAY 2686013 is a selective, allosteric antagonist of human pituitary adenylate cyclase activating polypeptide receptor (hPAC1-R) with IC50 of 0.92 and 0.4 uM in cAMP HTRF and Ca2+ release assays, respectively.

JKF-034 is an effective,blood-brain barrier (BBB) permeable small molecule inhibitor of hippocampal Rac1 activity, rescues learning deficits in APP/PS1 mice.

CS7171 is an effective, blood-brain barrier (BBB) permeable small molecule inhibitor of hippocampal Rac1 activity, rescues learning deficits in APP/PS1 mice.

1D-142 is a novel small molecule RHO family of GTPase RAC1 inhibitor, inhibits Rac1-GEF interaction and reduces Rac1-mediated TNFα-induced NF-κB nuclear translocation during cell proliferation and migration.

TY-2136 is a next generation ROS1/TRK/ALK inhibitor with IC50 of 1.6 nM and 460.1 nM for ROS1 G2032R and TRKA G595R, respectively, inhibits ROS1/TRK/ALK mutations and overcomes drug resistance due to acquired solvent-front mutations.

LY3358966 is a potent, selective inhibitor of the intestinal sodium-dependent phosphate cotransporter NPT2b (NaPi-2b, SLC34A2), inhibits phosphate uptake in human NPT2b expressed in CHO cells with IC50 of 32.4 nM.

EOS789 tosylate is a potent, pan-phosphate transporter (NaPi-2b, PiT-1, PiT-2) inhibitor, inhibits phosphate uptake in a noncompetitive manner for human NaPi-IIb, PiT-1, and PiT-2 with IC50 of 6.8, 1.5 and 1.7 uM, respectively.